Pulmonary Fibrosis Awareness Month may be coming to a close, but it's important to keep the momentum going, columnist Sam Kirton says.

Clinical trial results shared by Boehringer Ingelheim and Insilico Medicine showed improvement in idiopathic pulmonary ...

Aileron Therapeutics completes patient enrollment in Cohort 2 of phase 1b trial of LTI-03 in idiopathic pulmonary fibrosis: Austin, Texas Wednesday, September 25, 2024, 15:00 Hrs ...

Aileron Therapeutics, Inc. ("Aileron") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of ...

A University of Colorado professor won the 2024 Alton Ochsner Award for his work on disease risk factors for idiopathic ...

Interstitial Lung Disease (ILD) is a chronic condition marked by lung inflammation and scarring that makes breathing ...

The positive phase 3 results showed improved lung function with nerandomilast vs placebo at 52 weeks in idiopathic pulmonary ...

A new statistical technique developed by a researcher at the Texas A&M University School of Public Health and colleagues ...

Desaturation during the 6-minute walk test is a significant predictive factor for mortality in patients with idiopathic pulmonary fibrosis.

The Hong Kong headquartered company says its idiopathic pulmonary fibrosis drug performed well in a phase 2a trial and met ...

The most common breast cancer is HER2-negative, so called because it has low amounts of one of the proteins that contribute ...